Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
107.13
+5.09 (4.99%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $159.88M in the quarter ending March 31, 2026, with 43.28% growth. This brings the company's revenue in the last twelve months to $569.61M, up 50.19% year-over-year. In the year 2025, Mirum Pharmaceuticals had annual revenue of $521.31M with 54.74% growth.
Revenue (ttm)
$569.61M
Revenue Growth
+50.19%
P/S Ratio
11.47
Revenue / Employee
$1,362,701
Employees
418
Market Cap
6.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 521.31M | 184.42M | 54.74% |
| Dec 31, 2024 | 336.89M | 150.51M | 80.76% |
| Dec 31, 2023 | 186.37M | 109.31M | 141.85% |
| Dec 31, 2022 | 77.06M | 57.92M | 302.66% |
| Dec 31, 2021 | 19.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| Rhythm Pharmaceuticals | 217.17M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Centessa Pharmaceuticals | 15.00M |
MIRM News
- 4 days ago - Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens - TheFly
- 5 days ago - Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study - TheFly
- 5 days ago - Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Business Wire
- 6 days ago - Mirum Pharmaceuticals Slides: Study update presentation - Filings
- 8 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley - TheFly
- 15 days ago - Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026 - TheFly
- 15 days ago - Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - Business Wire